ClinicalTrials.gg
RecruitingNCT06990269Updated Nov 13, 2026

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

A Phase 2 interventional study of ADX-038 and Placebo in Geographic Atrophy Secondary to Age-related Macular Degeneration, sponsored by ADARx Pharmaceuticals, Inc.. Recruiting at 83 sites in 12 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by ADARx Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Nov 13, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Planned enrollment
36th of 107
240 · median 98
Started
2025
with 19 others
Phase 2
43 of 131
11 open now
Primary completion
2030-02
later than 40 of 44 live
Registered
112th of 131
by date

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 36th largest by planned enrollment of the 107 interventional ones that give a count, is one of 20 that started in 2025, is one of 43 in phase 2, reaches primary completion later than 40 of the 44 other live ones, and was the 112th registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.

03

Conditions studied

  • Geographic Atrophy Secondary to Age-related Macular Degeneration
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of GA of the macula secondary to AMD
  • GA lesions between 2.5 and 12.5 mm2 at screening
  • Sufficiently clear ocular media, adequate pupillary dilation and fixation to permit quality fundus imaging in the study eye as described in the protocol
  • Willing and able to comply with clinic visits and study-related procedures, including completion of the full series of meningococcal vaccinations and pneumococcal vaccination required per protocol

Exclusion criteria

Exclusion Criteria:

  • Has GA secondary to causes other than AMD
  • Has active ocular disease that compromises or confounds visual function
  • History of surgery for retinal detachment
  • Has ocular condition other than GA secondary to AMD
  • Use of intravitreal complement inhibitors in study eye
  • Hereditary or acquired complement deficiency
  • Active viral, bacterial or fungal infection
  • Liver injury as evidenced by abnormal liver function tests
  • Donating blood
  • History of choroidal neovascularization in the study eye
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Active - ADX-038

    Drug: ADX-038

  • Placebo comparator
    Placebo - Saline

    Drug: Placebo

Interventions

  • siRNA duplex oligonucleotide

    Also known as: siRNA

  • DrugPlacebo

    Saline

06

What researchers measure

Primary outcomes

  1. Evaluate the effect of ADX-038 on the preservation of the EZ layer

    Rate of change in the area of total EZ loss in the study eye from baseline to Month 12

    Time frame: 12 months

07

Study locations

43 of 83 sites recruiting
  • ADARx Clinical Site
    Gilbert, Arizona 85297, United States
    Recruiting
  • ADARx Clinical Site
    Phoenix, Arizona 85020, United States
    Recruiting
  • ADARx Clinical Site
    Bakersfield, California 93309, United States
    Recruiting
  • ADARx Clinical Site
    Beverly Hills, California 90211, United States
    Recruiting
  • ADARx Clinical Site
    Huntington Beach, California 93647, United States
    Recruiting
  • ADARx Clinical Site
    Poway, California 92064, United States
    Recruiting
  • ADARx Clinical Site
    Riverside, California 92505, United States
    Recruiting
  • ADARx Clinical Site
    Walnut Creek, California 94598, United States
    Recruiting
  • ADARx Clinical Site
    Orlando, Florida 32806, United States
    Recruiting
  • ADARx Clinical Site
    Wildwood, Florida 34785, United States
    Recruiting
  • ADARx Clinical Site
    Hagerstown, Maryland 21740, United States
    Recruiting
  • ADARx Clinical Site
    Reno, Nevada 89502, United States
    Recruiting
  • ADARx Clinical Site
    Erie, Pennsylvania 16505, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • ADARx Clinical Site
    Austin, Texas 78705, United States
    Recruiting
  • ADARx Clinical Site
    Bellaire, Texas 77401, United States
    Recruiting
  • ADARx Clinical Site
    Dallas, Texas 75231, United States
    Recruiting
  • ADARx Clinical Site
    McAllen, Texas 78503, United States
    Recruiting
  • ADARx Clinical Site
    Round Rock, Texas 78681, United States
    Recruiting
  • ADARx Clinical Site
    San Antonio, Texas 78340, United States
    Recruiting
  • ADARx Clinical Site
    The Woodlands, Texas 77384, United States
    Recruiting
  • ADARx Clinical Site
    St. George, Utah 84790, United States
    Recruiting
  • ADARx Clinical Site
    Albury, New South Wales 2640, Australia
    Recruiting
  • ADARx Clinical Site
    Hurstville, New South Wales 2220, Australia
    Recruiting
  • ADARx Clinical Site
    Parramatta, New South Wales 2150, Australia
    Recruiting
  • ADARx Clinical Site
    Sutherland, New South Wales 2232, Australia
    Recruiting
  • ADARx Clinical Site
    Sydney, New South Wales 2000, Australia
    Recruiting
  • ADARx Clinical Site
    East Melbourne, Victoria 3002, Australia
    Recruiting
  • ADARx Clinical Site
    Rowville, Victoria 3178, Australia
    Recruiting
  • ADARx Clinical Site
    Malvern, VIC 3144, Australia
    Recruiting
  • ADARx Clinical Site
    Sydney, NWS 2000, Australia
    Recruiting
  • ADARx Clinical Site
    Graz, Styria 8036, Austria
    Not yet recruiting
  • ADARx Clinical Site
    Innsbruck, Tyrol 6020, Austria
    Not yet recruiting
  • ADARx Clinical Site
    Vienna, 1090, Austria
    Not yet recruiting
  • ADARx Clinical Site
    Vienna, 1140, Austria
    Not yet recruiting
  • ADARx Clinical Site
    Edmonton, Alberta T5H 0X5, Canada
    Not yet recruiting
  • ADARx Clinical Site
    Vancouver, British Columbia V5Z 1M9, Canada
    Recruiting
  • ADARx Clinical Site
    Vancouver, British Columbia, Canada
    Recruiting
  • ADARx Clinical Site
    London, Ontario N6A4V2, Canada
    Not yet recruiting
  • ADARx Clinical Site
    Ottawa, Ontario K1H 8L6, Canada
    Recruiting
  • ADARx Clinical Site
    Ottawa, Ontario K2B 7E9, Canada
    Recruiting
  • ADARx Clinical Site
    Toronto, Ontario M3C 0G9, Canada
    Recruiting
  • ADARx Clinical Site
    Toronto, Ontario M8X 2X3, Canada
    Recruiting
  • ADARx Clinical Site
    Prague, 100 34, Czechia
    Not yet recruiting
  • ADARx Clinical Site
    Prague, 140 00, Czechia
    Not yet recruiting
  • ADARx Clinical Site
    Praha Klanovice, 12808, Czechia
    Not yet recruiting
  • ADARx Clinical Site
    Bonn, North Rhine-Westphalia 53127, Germany
    Not yet recruiting
  • ADARx Clinical Site
    Sulzbach, Saarland 66280, Germany
    Not yet recruiting
  • ADARx Clinical Site
    Cologne, 50937, Germany
    Not yet recruiting
  • ADARx Clinical Site
    Giessen, 35392, Germany
    Not yet recruiting
  • ADARx Clinical Site
    Mainz, 55122, Germany
    Not yet recruiting
  • ADARx Clinical Site
    München, 80336, Germany
    Not yet recruiting
  • ADARx Clinical Site
    Münster, 48149, Germany
    Not yet recruiting
  • ADARx Clinical Site
    Tübingen, 72076, Germany
    Not yet recruiting
  • ADARx Clinical Site
    Pécs, Baranya 7621, Hungary
    Not yet recruiting
  • ADARx Clinical Site
    Budapest, 1085, Hungary
    Not yet recruiting
  • ADARx Clinical Site
    Budapest, 1106, Hungary
    Not yet recruiting
  • ADARx Clinical Site
    Budapest, 1133, Hungary
    Not yet recruiting
  • ADARx Clinical Site
    Debrecen, 4032, Hungary
    Not yet recruiting
  • ADARx Clinical Site
    Milan, MI 20132, Italy
    Not yet recruiting
  • ADARx Clinical Site
    Roma, RM 00168, Italy
    Not yet recruiting
  • ADARx Clinical Site
    Milan, 20121, Italy
    Not yet recruiting
  • ADARx Clinical Site
    Milan, 20122, Italy
    Not yet recruiting
  • ADARx Clinical Site
    Milan, 20142, Italy
    Not yet recruiting
  • ADARx Clinical Site
    Novara, 28100, Italy
    Not yet recruiting
  • ADARx Clinical Site
    Padova, 35128, Italy
    Not yet recruiting
  • ADARx Clinical Site
    Coimbra, 3000-548, Portugal
    Not yet recruiting
  • ADARx Clinical Site
    Coimbra, 3004-561, Portugal
    Not yet recruiting
  • ADARx Clinical Site
    Coimbra, 3030-163, Portugal
    Not yet recruiting
  • ADARx Clinical Site
    Porto, 4200-319, Portugal
    Not yet recruiting
  • ADARx Clinical Site
    Barcelona, 08022, Spain
    Not yet recruiting
  • ADARx Clinical Site
    Barcelona, 08035, Spain
    Not yet recruiting
  • ADARx Clinical Site
    Barcelona, 08908, Spain
    Not yet recruiting
  • ADARx Clinical Site
    Madrid, 28040, Spain
    Not yet recruiting
  • ADARx Clinical Site
    Valencia, 46004, Spain
    Not yet recruiting
  • ADARx Clinical Site
    Olten, Canton of Solothurn 4600, Switzerland
    Not yet recruiting
  • ADARx Clinical Site
    Basel, 4031, Switzerland
    Recruiting
  • ADARx Clinical Site
    Bern, 3010, Switzerland
    Recruiting
  • ADARx Clinical Site
    Liverpool, BC L7 8XP, United Kingdom
    Recruiting
  • ADARx Clinical Site
    Dorchester, Dorset DT1 2JY, United Kingdom
    Recruiting
  • ADARx Clinical Site
    Wolverhampton, West Midlands WV10 0QP, United Kingdom
    Recruiting
  • ADARx Clinical Site
    London, NW10 7NS, United Kingdom
    Recruiting
  • ADARx Clinical Site
    London, SW17 0QT, United Kingdom
    Recruiting
  • ADARx Clinical Site
    Sunderland, SR1 3AE, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Feb 2030, 51 months after the start.

Of 24 phase 2 interventional studies under Geographic Atrophy, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 54. This study's planned 51 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2025
First posted
May 25, 2025
StartActual
Nov 10, 2025
Primary completionEst.
Feb 28, 2030
CompletionEst.
Aug 30, 2030
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • ADARx Clinical Site · Riverside, United StatesNot yet recruiting→Recruiting
  • ADARx Clinical Site · Ottawa, CanadaNot yet recruiting→Recruiting
  • ADARx Clinical Site · Dorchester, United KingdomNot yet recruiting→Recruiting
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • ADARx Clinical Site · Riverside, United StatesNot yet recruiting→Recruiting
    • ADARx Clinical Site · Ottawa, CanadaNot yet recruiting→Recruiting
    • ADARx Clinical Site · Dorchester, United KingdomNot yet recruiting→Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06990269
Lead sponsor
ADARx Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
May 25, 2025
Start date
Nov 10, 2025
Primary completion
Feb 28, 2030 (estimated)
Completion
Aug 30, 2030 (estimated)
Last update
Nov 13, 2026

Study contacts

Nali Castillo
Contact
info@adarx.com
877-232-7974
Wendy Murahashi
study director · ADARx Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ADX-038

Start the discussion